HR-010 (Hrain Biotechnology)

Primary objective: To evaluate the safety and tolerability of anti-human CD70 T cell injection in the treatment of patients with advanced/metastatic renal cell carcinoma. Secondary objectives: (1) To evaluate the in vivo expansion and survival of anti-human CD70 T cells after infusion of anti-human CD70 T cell injection; (2) To preliminarily evaluate the objective response rate (ORR) after infusion of anti-human CD70 T cell therapy in patients with advanced/metastatic renal cell carcinoma; (3) To evaluate the duration of overall response (DOR) in patients with advanced/metastatic renal cell carcinoma treated with anti-human CD70 T cell injection; (4) To evaluate the progression-free survival (PFS) in patients with advanced/metastatic renal cell carcinoma treated with anti-human CD70 T cell injection; (5) To evaluate the overall survival (OS) in patients with advanced/metastatic renal cell carcinoma treated with anti-human CD70 T cell injection; (6) To evaluate the immunogenicity of anti-human CD70 T cell injection.